NO20033273L - Anvendelse av (R)-ibuprofen-metansulfonamid og salter derav til behandlingog forhindring av avstötning av transplanterte organer - Google Patents

Anvendelse av (R)-ibuprofen-metansulfonamid og salter derav til behandlingog forhindring av avstötning av transplanterte organer

Info

Publication number
NO20033273L
NO20033273L NO20033273A NO20033273A NO20033273L NO 20033273 L NO20033273 L NO 20033273L NO 20033273 A NO20033273 A NO 20033273A NO 20033273 A NO20033273 A NO 20033273A NO 20033273 L NO20033273 L NO 20033273L
Authority
NO
Norway
Prior art keywords
prevention
treatment
methanesulfonamide
ibuprofen
rejection
Prior art date
Application number
NO20033273A
Other languages
English (en)
Other versions
NO334285B1 (no
NO20033273D0 (no
Inventor
Riccardo Bertini
Francesco Colotta
Roberto Novellini
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of NO20033273L publication Critical patent/NO20033273L/no
Publication of NO20033273D0 publication Critical patent/NO20033273D0/no
Publication of NO334285B1 publication Critical patent/NO334285B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20033273A 2001-02-02 2003-07-18 Anvendelse av (R)-ibuprofen-metansulfonamid og salter derav til behandling og forhindring av avstøtning av transplanterte organer NO334285B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (3)

Publication Number Publication Date
NO20033273L true NO20033273L (no) 2003-07-18
NO20033273D0 NO20033273D0 (no) 2003-07-18
NO334285B1 NO334285B1 (no) 2014-01-27

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033273A NO334285B1 (no) 2001-02-02 2003-07-18 Anvendelse av (R)-ibuprofen-metansulfonamid og salter derav til behandling og forhindring av avstøtning av transplanterte organer

Country Status (26)

Country Link
US (1) US7560487B2 (no)
EP (1) EP1355641B1 (no)
JP (1) JP2004517948A (no)
KR (1) KR100857898B1 (no)
CN (1) CN1561205A (no)
AT (1) ATE304846T1 (no)
AU (1) AU2002250869B2 (no)
BR (2) BR0206804A (no)
CA (1) CA2432432C (no)
CZ (1) CZ303665B6 (no)
DE (1) DE60206245T2 (no)
DK (1) DK1355641T3 (no)
EE (1) EE05233B1 (no)
ES (1) ES2248541T3 (no)
HU (1) HU229070B1 (no)
IL (1) IL157180A (no)
IT (1) ITMI20010206A1 (no)
MX (1) MXPA03006686A (no)
NO (1) NO334285B1 (no)
NZ (1) NZ526655A (no)
PL (1) PL215109B1 (no)
PT (1) PT1355641E (no)
RU (1) RU2257895C2 (no)
SK (1) SK287632B6 (no)
WO (1) WO2002062330A2 (no)
ZA (1) ZA200304861B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1579859T1 (sl) * 2004-03-25 2007-04-30 Dompe Pha R Ma Spa Res & Mfg Uporaba n-(2-aril-propionil)-sulfonamidov za zdravljenje poskodbe hrbtnega mozga
JP2008545627A (ja) 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
CN101677999A (zh) * 2006-11-13 2010-03-24 塔普医药产品公司 使用黄嘌呤氧化还原酶抑制剂保护肾功能的方法
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
WO2012033941A1 (en) 2010-09-10 2012-03-15 Takeda Pharmaceuticals North America, Inc. Methods for concomitant treatment of theophylline and febuxostat
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
CA3055004C (en) * 2017-03-15 2023-10-03 Numares Ag Use of a marker set for determining the risk of kidney rejection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Also Published As

Publication number Publication date
PL215109B1 (pl) 2013-10-31
NO334285B1 (no) 2014-01-27
DE60206245D1 (de) 2006-02-02
KR20030074725A (ko) 2003-09-19
PT1355641E (pt) 2005-11-30
CA2432432A1 (en) 2002-08-15
NO20033273D0 (no) 2003-07-18
ZA200304861B (en) 2004-06-30
AU2002250869B2 (en) 2006-10-19
SK287632B6 (sk) 2011-04-05
WO2002062330A3 (en) 2003-04-03
US20040102520A1 (en) 2004-05-27
HU229070B1 (hu) 2013-07-29
DK1355641T3 (da) 2005-10-17
WO2002062330A2 (en) 2002-08-15
NZ526655A (en) 2005-02-25
KR100857898B1 (ko) 2008-09-10
ATE304846T1 (de) 2005-10-15
US7560487B2 (en) 2009-07-14
HUP0303024A3 (en) 2005-07-28
RU2003126600A (ru) 2005-02-27
EP1355641A2 (en) 2003-10-29
ES2248541T3 (es) 2006-03-16
CZ303665B6 (cs) 2013-02-20
BRPI0206804B1 (pt) 2018-09-25
MXPA03006686A (es) 2004-05-31
EP1355641B1 (en) 2005-09-21
EE200300340A (et) 2003-10-15
DE60206245T2 (de) 2006-06-14
CZ20032095A3 (en) 2004-05-12
JP2004517948A (ja) 2004-06-17
SK9732003A3 (en) 2003-11-04
ITMI20010206A1 (it) 2002-08-02
HUP0303024A2 (hu) 2003-12-29
BR0206804A (pt) 2004-02-03
CN1561205A (zh) 2005-01-05
IL157180A (en) 2009-06-15
CA2432432C (en) 2008-03-25
RU2257895C2 (ru) 2005-08-10
PL363576A1 (en) 2004-11-29
EE05233B1 (et) 2009-12-15

Similar Documents

Publication Publication Date Title
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
PT1091747E (pt) Utilizacao de solucoes salinas isotermicas para a prevencao de inflamacoes
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE248837T1 (de) Chinuclidin-acrylamide
DE50310516D1 (de) Fredericamycin-derivate
DE60118604D1 (de) Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
MXPA05004247A (es) Cromonas y derivados de cromona y usos de los mismos.
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
NO20033273L (no) Anvendelse av (R)-ibuprofen-metansulfonamid og salter derav til behandlingog forhindring av avstötning av transplanterte organer
ATE521344T1 (de) Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen
DE60313356D1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
PT1091746E (pt) Utilizacao de solucoes salinas isoosmoticas para a preparacao de medicamentos cerumenoliticos
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
WO2003039231A3 (en) Compounds and methods for treating transplant rejection
PL1514545T3 (pl) Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich
TH67520A (th) การรักษาหน้าที่เนื้อเยื่อปลูกถ่ายที่ช้า
RU2000115437A (ru) Способ лечения бронхиальной астмы

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: DOMPE FARMACEUTICI S.P.A., IT

MM1K Lapsed by not paying the annual fees